MEDIUMBuilt-inCustomer
40%
poultry industry MFA sales
“10-K Item 1A: 'Approximately 40% of our MFAs and other sales in fiscal year 2025 were to the poultry industry'”
PAHC · Concentration risk · 10-K extracted
Phibro Animal Health Corporatio (PAHC) concentration risks
Updated
The most significant concentration Phibro Animal Health Corporatio discloses is poultry industry MFA sales at 40%, classified MEDIUM by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Phibro Animal Health Corporatio’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH0
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-10-11Phibro's disclosed concentration is a single end-market exposure rather than a counterparty one. Approximately 40% of its MFAs and other sales in fiscal year 2025 were to the poultry industry, a medium-share exposure that the filing frames as structural. Because the dependency sits with an industry rather than a named customer, the relevant swing factors are sector-wide: flock economics, disease cycles and producer purchasing decisions would move results together across the customer base. That is a different risk from losing an individual account, and it is not something management can diversify away quickly within the MFA product line. Taken together, the disclosure points to a business whose revenue durability is tied to one animal-protein channel. The filing identifies no single customer, supplier or geographic concentration in the sources reviewed, so this industry exposure is the main lens for judging how much concentration risk could move the verdict. It is clearly disclosed in the most recent 10-K and sizeable enough to merit monitoring.
For the engine’s reasoning on PAHC’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Drug Manufacturers - Specialty & Generic
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ANIP | ANI Pharmaceuticals, Inc. | 2 | 1 | 0 | 3 |
| AMLX | Amylyx Pharmaceuticals, Inc. | 2 | 0 | 0 | 2 |
| AMPH | Amphastar Pharmaceuticals, Inc. | 1 | 2 | 1 | 4 |
| AMRX | Amneal Pharmaceuticals, Inc. | 1 | 1 | 0 | 2 |
| ALKS | Alkermes plc | 0 | 1 | 1 | 2 |
| PAHC● | Phibro Animal Health Corporatio | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.